6:12PM Advent Software earnings color (ADVS) 20.61 +0.37: -- Update -- Reuters Research is indicating that excluding items actual of a $0.04 loss is comparable to the $0.02 consensus... see 16:35 update for full earnings comment.
6:10PM Business Week discusses TELK : Business Week states that Telik (TELK) may be the next biotech buyout. So says Mark Monane of Needham, best known for calling the Pfizer (PFE) purchase of Esperion (ESPR). As of today's close TELK has soared to $24.00 up from Feb. level of $10.00. Monane says TELK could be next because its Telcyta is the "most promising unpartnered, small-molecule compound in late-stage development." Monane expects FDA approval for Telcyta by 2006. Telcyta targets breast, colon, lung, and ovarian cancer. With $222 mln in cash, TELK could bring Telcyta to market but Monane sees TELK finding a European marketing partner this year that could end up buying it. Possible partners include Aventis (AVE) or GlaxoSmithKline (GSK).
6:10PM Allmerica Earnings Color (AFC) 20.61 +0.37: -- Update -- Reuters Reseach is telling us that the comparable actual is $0.57, excluding multiple items...see the 16:58 comment for the full earnings report.
6:04PM PeopleSoft color (PSFT) 22.99 -0.04: -- Update -- We are hearing that PSFT is trading down after hours because company failed to meet heightened expectations for license revs.
5:59PM BIV mentioned favorably in Business Week : Business Week comments on well-known investors who are buying Bioenvision (BIV), most notably a 27% accumulation of shares by George Soros. At today's close the stock is trading at $5.18, up 241% from the July level of $2.15. Peter Cardillo, chief strategist at S.W. Bach, says BIV is undervalued not only because of the potential of its two staple drugs, Modrenal and Clofarabine, but also because it could be acquired. A logical buyer is Schering (SHR) or Bristol-Myers Squibb (BMY), he says, adding the stock is worth $10.00 in a buyout. CFO David Luci says BIV is looking for partners and concedes that some big companies are interested. The issue before the board, on which Soros is represented, is whether to go it alone or seek a merger to take advantage of the $1 bln market potential for Clofarabine..
5:52PM PeopleSoft beats by a penny, ex items (PSFT) 21.81 -1.17: Reports Q4 (Dec) pro forma earnings of $0.20 per share, excluding impact of deferred maintenance write-down of ($0.08), amortization of capitalized software and intangible assets of ($0.05), and restructuring charges of ($0.02), $0.01 better than the Reuters Research consensus of $0.19; revenues rose 33.7% year/year to $685.2 mln vs the $666.2 mln consensus.
5:51PM PeopleSoft license revs $185, at high end of guidance (PSFT) 22.99 -0.04:
5:51PM MicroStrategy reports EPS of $0.67 (MSTR) 53.50 -2.18: -- Update -- Reuters Research is indicating that excluding items the $0.67 actual is comparable to the $0.46 consensus... see 16:26 entry for full earnings comment.
5:51PM PeopleSoft beats Reuters conensus by $0.01, in line with First Call (PSFT) 22.99 -0.04:
5:47PM USF Corp reports results (USFC) 35.77 +0.47: Reports Q4 (Dec) earnings of $0.68, which includes ex items and is not comparable to consensus. After backing out a $5.5 mln net after-tax benefit or $0.20 per share ($6.1 mln gain from sale of a terminal net of a $0.6 mln restructuring charge.), we came up with $0.48 per share. Reuters Research consensus is $0.49, in touch with Reuters to confirm comparable actual; revenues fell 5.9% year/year to $546.6 mln vs the $572.8 mln consensus.
5:39PM Business Week comments on HON future : Business Week states that many analysts are sour on Honeywell International (HON), but some investors are buying shares because they smell a takeover. The talk is that United Technologies (UTX) will make a third pass. UTX made a bid in Oct but was edged out by General Electric (GE). The European Commission blocked GE's bid and UTX tried again but was turned down flat. John Inch of Merrill Lynch, who tags the stock a buy just on fundamentals, says UTX is still very interested -- and frustrated. But he doubts Honeywell is eager for a deal Honeywell rose from $26.00 in Sept to $35.95 at today's close. Richard Steinberg of Steinberg Global Asset Mgmt, who owns shares, says aerospace is poised to turn around, which would be a boon to HON.
5:39PM Chordiant Sftwr reports, guides in line (CHRD) 5.20 -0.23: Reports Q4 (Dec) earnings of $0.02 per share, in line with the Reuters Research consensus of $0.02; revenues rose 14.6% year/year to $19.6 mln vs the $18.9 mln consensus. Company sees Q1 revenues of $19-20 mln, consensus $19.1 mln.
5:32PM Overnite beats by $0.04, affirms Q1 (OVNT) 22.98 -0.05: Reports Q4 (Dec) earnings of $0.38 per share, ex-items, $0.04 better than the Reuters Research consensus of $0.34; revenues rose 7.7% year/year to $378.1 mln vs the $372.0 mln consensus. Co sees Q1 (Mar) EPS of $0.19-$0.24 vs consensus of $0.21.
5:32PM VeriSign provides mixed Q1 guidance (VRSN) 16.35 -1.41: -- Update -- On the conference call, management indicates that Q1 revenues are expected to be approximately $220 mln and EPS roughly $0.13. This compares to Reuters Research consensus of $228 mln in revenues and earnings of $0.13 per share. Gross margins are expected to be relatively flat at 60%, with operating margins in the 19-20% range.
5:28PM Roxio to consolidate offices, management teams (ROXI) 4.20 -0.15: Company announces it will consolidate management teams into Napster's L.A. office, Brad Duea, Head of Bus Dev, will become President, position held currently by Mike Bebel, who will "wind down" his New York based duties.
5:15PM Universal Health preannounces Q4 EPS below consensus, guides Y04 EPS below, revs above (UHS) 52.25 -0.15: Company expects to report adjusted Q4 EPS $0.73 vs the Reuters Research consensus of $0.75. Co also guides Y04, sees EPS of $3.43-3.53, vs the R.R. consensus of $3.56, and revenues exceeding $4.2 bln; the R.R. consensus is $4.02 bln.
5:09PM RadiSys reports for Q4, beats on revs (RSYS) 22.21 -0.64: Co is reporting Q4 (Dec) EPS of $0.08, which includes a $1.8 mln loss on sale of a building and a $200K gain on reversal of restructuring charge. After backing out these items co's EPS is approx $0.17. We are checking with Reuters for a comparable number against their consensus of $0.14 per share: revenues rose 17.0% year/year to $55.3 mln vs the $51.8 mln consensus.
5:09PM General Dynamics wins $8.4 bln multi-year contract (GD) 93.66 +1.21: Co announces that the U.S. Navy has entered into an $8.4 bln multi-year contract with General Dynamics Electric Boat for the procurement of 5 Virginia-class attack submarines from FY04 through FY08.
5:07PM Duquesne Light reports (DQE) 18.63 -0.02: Reports Q4 (Dec) earnings of $0.19 per share, $0.01 worse than the Reuters Research consensus of $0.20 and $0.01 better than First Call consensus of $0.18. Company affirms its Y04 earnings guidance of $80-85 mln.
5:07PM IMPAC Mortgage announces $100 mln common stock offering (IMH) 20.33 +0.63:
5:06PM Gateway reports in-line Q4 results (GTW) 4.09 +0.04: Reports Q4 (Dec) loss of $0.15 per share, in line with the Reuters Research consensus of ($0.15); revenues fell 17.2% year/year to $875.1 mln vs guidance of approx $880 mln and consensus of $880.2 mln.
5:03PM TELK: Telik may be the next biotech buyout -- Business Week 24.00 +0.30: Also mentioned in Business Week are Bioenvision (BIV) -- George Soros has accumulated 27% stake in little-known biopharma; and Honeywell (HON) -- many analysts are sour on Honeywell, "but some investors are buying shares because they smell a takeover."
5:03PM Chartered Semi reports in line, guides Q1 above consensus (CHRT) 10.16 -0.34: Reports Q4 (Dec) loss of $0.17 per ADS, in line with the Reuters Research consensus of ($0.17); revenues rose 69.4% year/year to $182.8 mln vs the $174.1 mln consensus. Co also guides Q1, sees loss per ADS of $0.05 to loss of $0.01, vs the R.R. consensus of ($0.19), and revenues of $221-227 mln, excluding CHRT's share of SMP, vs an estimate of $170.5 mln.
5:01PM Newport beats by $0.01; guides higher for Q1 (NEWP) 19.72 -0.24: Reports Q4 (Dec) loss of $(0.03) per share, excluding a $1.0 mln pre-tax or a $0.01 after-tax per share restructuring and impairment charge, $0.01 better than the Reuters Research consensus of ($0.04); revenues rose 11.7% year/year to $36.2 mln vs the $35.4 mln consensus. For Q1, co expects sales and EPS of $38.0-$39.5 mln and $0.00-$0.02 vs consensus of $36.9 mln and $(0.02).
4:59PM Guitar Center beats by $0.03; reaffirms Q1 guidance (GTRC) 32.75 -0.13: Reports Q4 (Dec) earnings of $0.78 per share, $0.03 better than the Reuters Research consensus of $0.75; revenues rose 18.2% year/year to $395.8 mln vs the $393.3 mln consensus. Co reaffirms Q1 (Mar) EPS guidance of $0.31-0.34 and revenues in the range of $323-334 mln, Reuters consensus is $0.32 and $329, respectively.
4:58PM Allmerica reports (AFC) 34.45 -0.25: Reports Q4 (Dec) earnings of $0.57 per share, excluding multiple items, $0.26 better than the Reuters Research consensus of $0.31.
4:55PM RSA Security reports in line; guides Q1 in line (RSAS) 15.53 -0.26: Reports Q4 (Dec) earnings of $0.10 per share, in line with the Reuters Research consensus of $0.10; revenues rose 15.9% year/year to $70.7 mln vs the $68.2 mln consensus. Company sees Q1 EPS of $0.06-0.09 on revs $68-71 mln vs the R.R. consensus of $0.08 & $67.1 mln respectively.
4:52PM Micrel tops consensus (MCRL) 16.70 -0.48: Reports Q4 (Dec) earnings of $0.05 per share, excluding a half-penny charge for stock compensation expense, $0.02 better than the Reuters Research consensus of $0.03; revenues rose 15.1% year/year to $58.3 mln vs the $57.2 mln consensus.
4:52PM Columbia Sportswear beats by $0.02 (COLM) 53.66 +0.53: Reports Q4 (Dec) earnings of $0.79 per share, $0.02 better than the Reuters Research consensus of $0.77; revenues rose 18.5% year/year to $257.4 mln vs the $249.0 mln consensus. For Q104, co sees net income growth of 14-16% and year-over-year revenue growth of 19-21%.
4:50PM Telecom/Networking stocks lift on Nortel report: AVCI +0.80, CSCO +0.40, JNPR +0.32, CIEN +0.30 :
4:49PM Nortel Earnings Color (NT) 7.94 +1.36: -- Update -- Reuters Research is indicating that excluding items the $0.09 actual is comparable to the $0.02 consensus... see 16:22 update for full earnings comment.
4:48PM Ascential beats by a penny, issues guidance (ASCL) 24.08 -0.80: Reports Q4 (Dec) earnings of $0.09 per share, $0.01 better than the Reuters Research consensus of $0.08; revenues rose 89.1% year/year to $64.5 mln vs the $63.2 mln consensus. Co expects Q1 revenue of $61-$64 mln (consensus $61.9 mln), and expects 2004 rev of $265-$275 mln (consensus $273.2 mln); co continues to anticipate GAAP profitability in each qtr of 2004.
4:47PM Avid Tech beats Q4 consensus, beat on revs (AVID) 48.97 -4.13: Co is reporting Q4 EPS of $0.47, which includes a $1.3 mln restructuring charge. After backing out charge co's Q4 EPS is approx $0.51, ex items. Reuters Research consensus of $0.46, checking with Reuters for a comparable number, but the co beat consensus either way; revenues rose 12.9% year/year to $127.3 mln vs the $125.4 mln consensus.
4:46PM Neurocrine Biosci reports (NBIX) 57.55 +0.18: Reports Q4 (Dec) earnings of $0.09 per diluted share, which includes a gain of $18.0 mln, or approx $0.48 per share, related to sale of current corporate facility, may not be comparable to the Reuters Research consensus of ($0.12); revenues rose 599.5% year/year to $27.1 mln vs the $35.1 mln consensus. Co anticipates 2004 to be a pivotal yearas it transitions from an R&D biotech company to a fully integrated pharmaceutical company.
4:45PM Eastman Chem beats, guides in line (EMN) 38.50 +0.15: Reports Q4 (Dec) earnings of $0.13 per share, "excluding certain items", $0.11 better than the Reuters Research consensus of $0.02; revenues rose 9.0% year/year to $1.43 bln vs the $1.38 bln consensus. Company sees Q1 EPS in line with consensus of $0.22.
4:41PM Intl Rectifier beats by $0.02, pro forma (IRF) 48.25 +0.03: Reports Q2 (Dec) earnings of $0.36 per share, pro forma, $0.02 better than the Reuters Research consensus of $0.34; revenues rose 20.4% year/year to $252.3 mln vs the $248.7 mln consensus.
4:41PM Exult reports in-line (EXLT) 7.10 -0.19: Reports Q4 (Dec) earnings of $0.05 per share, in line with the Reuters Research consensus of $0.05; revenues fell less than 1% to $117.9 mln. Note, revenue consensus was $132.7 mln, however, in Nov 2003, the co decided to sell certain assets and to divest the Gunn Partners consulting unit. The latter is now considered discontinued operations and is excluded from the $117.9 mln figure, but it appears that revenue from Gunn remained in the consensus.
4:39PM Magma Design beats by $0.02, ex items, beats on revs; guides in line for Q1 (LAVA) 26.76 +0.05: Reports Q3 (Dec) earnings of $0.16 per share, $0.02 better than the Reuters Research consensus of $0.14; revenues rose 66.3% year/year to $31.1 mln vs the $28.6 mln consensus. Co sees Q4 (Mar) EPS of $0.15-0.19, ex items, and revenues in the range of $32-34 mln, Reuters consensus is $0.17 and $32 mln, respectively.
4:38PM InterMune reports Q4 results, issues guidance (ITMN) 19.28 -0.30: Reports Q4 (Dec) loss of $0.73 per share, $0.41 better than the Reuters Research consensus of ($1.14); total net revenues rose 1.3% year/year to $39.8 mln vs the $40.1 mln consensus. Co expects 2004 total net product sales of $150-$180 mln, vs consensus of $177.4 mln; net product sales for Actimmune are projected to be in the range of $130-$155 mln for the year, and sales of Infergen are expected to be between $17-$22 mln.
4:35PM Borland beats by $0.02, ex items; guides in line (BORL) 9.30 -0.05: Reports Q4 (Dec) earnings of $0.06 per share, ex items, $0.02 better than the Reuters Research consensus of $0.04; revenues rose 10.4% year/year to $74.0 mln vs the $72.0 mln consensus. Company sees Q1 EPS of $0.03-0.05 vs the Reuters Research consensus of $0.04, on revs of $71-75 mln vs consensus of $72.7 mln.
4:35PM Advent Software reports, guides Q1 & Y04 revs in line (ADVS) 20.61 +0.37: Reports Q4 (Dec) earnings of $0.07 per share, excluding charges of approx ($2.38) related to tax provision of $70.5 mln, to record full valuation allowance against deferred tax assets, restructuring and impairment charges and amortization of intangibles of $5.9 mln, and a $1.8 mln write-off of internally developed software, may not be comparable to the Reuters Research consensus of $0.02; revenues rose 1.7% year/year to $36.9 mln vs the $36.3 mln consensus. Co also guides, sees Q1 revenues of $33.5-35.5 mln, vs an R.R. estimate $33.7 mln, and sees Y04 revenues of $145-150 mln vs an estimate of $145.6 mln. In touch with Reuters Research.
4:34PM Dendrite beats by $0.05, ex items; guides Q1 EPS above consensus (DRTE) 14.26 -0.22: Reports Q4 (Dec) earnings of $0.20 per share, $0.05 better than the Reuters Research consensus of $0.15; revenues rose 73.6% year/year to $99.0 mln.
4:34PM Tripos announces 10% reduction in Pfizer contract value (TRPS) 6.58 +0.17: Co announces an amendment to its strategic collaboration with Pfizer (PFE) for the design, synthesis and purification of druglike compounds. Tripos will reduce file enrichment activities with Pfizer, but partially offsetting this reduction, Tripos will engage in new work for Pfizer in the areas of hit follow-up and large library production.. Terms of the amended agreement result in a decrease in the total contract value of approx 10%, with the bulk of the reduction occurring in 2005.
4:33PM Exponent reports in-line (EXPO) 24.29 -0.06: Reports Q4 (Dec) earnings of $0.27 per share, in line with the Reuters Research consensus of $0.27; revenues rose 4.4% year/year to $34.3 mln vs the $31.7 mln consensus.
4:33PM LAVA prelim $0.16, 2 cents ahead; revs $31.1 mln vs $28.6 mln consensus :
4:32PM LivePerson reports in-line Q4, issues guidance (LPSN) 5.34 -0.32: Co reports Q4 EPS of $0.01 on $3.5 mln in sales, in-line with consensus of $0.01 and $3.45 mln. Co expects Q1 GAAP EPS of $0.01 on $4.0 mln in sales (consensus $0.02 and $3.92 mln), and expects 2004 GAAP EPS of $0.08 on $18.5 mln in sales (consensus $0.12 and $18.8 mln)... EPS ests may not be comparable, since it is unclear whether Q1 and 2004 EPS ests are GAAP or pro forma.
4:31PM PIXR resumes trading, advances 1.80 pts :
4:29PM Digital Insight beats by $0.02 (DGIN) 25.05 +0.96: Reports Q4 (Dec) earnings of $0.22 per share, ex items, $0.02 better than the Reuters Research consensus of $0.20; revenues rose 22.9% year/year to $42.2 mln vs the $40.9 mln consensus. Company sees Q1 pro forma EPS of $0.21-0.22 vs consensus of $0.21 on revs of $45-45.5 mln, consensus $42.8 mln. DGIN sees Y04 EPS of $0.92-0.96 vs consensus of $0.94 on revs of $193-197 mln, consensus is $179 mln.
4:29PM Packeteer reports in line (PKTR) 18.96 -0.44: Reports Q4 (Dec) earnings of $0.10 per share, in line with the Reuters Research consensus of $0.10; revenues rose 28.2% year/year to $20.0 mln vs the $19.5 mln consensus.
4:27PM Varian Semi beats by $0.02; guides sharply higher for MarQ (VSEA) 43.73 -0.12: Reports Q1 (Dec) earnings of $0.13 per share, $0.02 better than the Reuters Research consensus of $0.11; revenues rose 21.7% year/year to $101.8 mln vs the $100.0 mln consensus. Co expects Q2 (Mar) revenue and EPS of $120-$130 mln and $0.32-$0.40 vs consensus of $109 mln and $0.17.
4:26PM MicroStrategy reports for Q4, beats on revs; guides for Q1 and Y04 (MSTR) 53.50 -2.18: Co is reporting Q4 EPS of $1.02 which contains numerous gains. After backing out a $800K gain from discontinued operations and a $5.2 mln tax benefit, EPS is approx $0.63. We are checking with Reuters for a comparable number against the Reuters Research consensus of $0.46. But it does appear that the company has beaten estimates; revenues rose 23.1% year/year to $51.7 mln vs the $45.5 mln consensus. Co also beats on license revenues, reporting $23.4 mln vs Briefing.com license revenues consensus of $19.8 mln (2 analyst in survey). Co also sees Q1 GAAP EPS in the range of $0.14-0.26 and revenues in the range of $40-43 mln, consensus is $45 mln. Y04 GAAP EPS is in the range of $1.79-1.90 and revenues are in the range of $185-195 mln, consensus is $184 mln.
4:26PM Actuate reports in line, ex items (ACTU) 3.24 -0.07: Reports Q4 (Dec) non-GAAP earnings of $0.02 per diluted share, in line with the Reuters Research consensus of $0.02; revenues rose 0.4% year/year to $27.4 mln vs the $27.4 mln consensus.
4:22PM Nortel beats, guides (NT) 6.59 +0.13: Reports Q4 (Dec) earnings of $0.09 per share, $0.07 better than Reuters Research consensus of $0.02; revenues rose 11.9% year/year to $2.83 bln vs the $2.44 bln consensus. Company says it expects "seasonal decline" from this quarter's revenues of $2.83 bln, consensus $2.33 bln.
4:22PM CNET beats by $0.02 (CNET) 8.19 -0.25: Reports Q4 (Dec) earnings of $0.05 per share, $0.02 better than the Reuters Research consensus of $0.03; revenues rose 8.4% year/year to $73.5 mln vs the $70.1 mln consensus. For Q1, co sees total revenue of $60-$62 mln vs consensus of $60.8 mln.
4:19PM Yellow Roadway misses by $0.07, ex items, guides Q1 below consensus, Y04 in line (YELL) 36.41 +0.33: Reports Q4 (Dec) adjusted earnings of $0.71 per diluted share, excluding $0.73 per share of costs primarily attributed to acquisition of Roadway and its results of operations, $0.07 worse than the Reuters Research consensus of $0.78; revenues rose 18.5% year/year to $903.4 mln vs the $930.3 mln consensus. Co also guides, sees Q1 EPS of $0.25-0.35, vs the R.R. consensus of $0.36, and Y04 EPS of $2.70-3.30, vs the R.R. consensus of $3.08.
4:19PM TEKELEC beats by $0.03, ex items; guides (TKLC) 18.02 -0.01: Reports Q4 (Dec) earnings of $0.13 per share, ex items, $0.03 better than the Reuters Research consensus of $0.10; revenues rose 28.4% year/year to $75.0 mln vs the $73.1 mln consensus. Company sees Q1 EPS of $0.05-0.07 on revs of $73-75 mln vs the R.R. consensus of $0.07 & $68.32 respectively.
4:18PM BE Aerospace lowers Q4 guidance due to worsening conditions in the biz jet industry, weak dollar (BEAV) 6.26 -0.62:
4:16PM MicroStrategy beat on license revs, $23.4 mln vs consensus $19.8 mln :
4:16PM Avnet beats by $0.03 (AVT) 24.46 -1.13: Reports Q2 (Dec) earnings of $0.21 per share, ex-items, $0.03 better than the Reuters Research consensus of $0.18; revenues rose 8.9% year/year to $2.55 bln vs the $2.53 bln consensus.
4:12PM Lexar Media beats by a nickel, guides EPS below consensus (LEXR) 15.44 -0.21: Reports Q4 (Dec) earnings of $0.21 per share, $0.05 better than the Reuters Research consensus of $0.16; total revenues rose 171.0% year/year to $177.5 mln vs the $141.1 mln consensus. Co expects Q1 EPS of $0.10 in EPS on $140 mln in sales (consensus $0.13 and $121.1 mln), and expects 2004 EPS of $0.60 (consensus is $0.67).
4:12PM RealNetworks beats by $0.01, ex items, guides Q1 EPS below consensus (RNWK) 6.14 -0.30: Reports Q4 (Dec) non-GAAP loss of $0.02 per share, excluding ($0.01) related to litigation expenses, $0.01 better than the Reuters Research consensus of ($0.03); revenues rose 17.0% year/year to $54.1 mln vs the $54.8 mln consensus. Co also guides Q1, sees loss of $0.02 to loss of $0.03, vs the R.R. consensus of ($0.01), and revenues of $56-59 mln, vs an estimate of $57.8 mln.
4:12PM VeriSign beats by $0.04 (VRSN) 17.76 -0.86: Reports Q4 (Dec) fully taxed, pro forma earnings of $0.17 per share, $0.04 better than the Reuters Research consensus of $0.13; revenues fell 8.5% year/year to $251.6 mln vs the $244.7 mln consensus. Company reported $0.18 per share on an untaxed basis.
4:11PM LEXR turns south on guidance; watch for potential weakness in SNDK :
4:11PM California Pizza reports in line, guides Q1 below consensus (CPKI) 18.10 -0.31: Reports Q4 (Dec) earnings of $0.22 per share, in line with the Reuters Research consensus of $0.22; revenues rose 17.8% year/year to $96.0 mln vs the $95.5 mln consensus. Company sees Q1 EPS of $0.17-0.19 vs consensus of $0.23, reaffirms Y04 outlook of $0.95-1.05 vs consensus of $0.96.
4:11PM Adobe Systems increases Q1 guidance (ADBE) 36.13 -0.51: Based on strong results thus far in the quarter Co says it will exceed previous financial targets provided. Increases it Q1 (Feb) EPS to $0.36-0.42 (previously $0.33-0.36), Reuters consensus is $0.35 and revenues to the range of $380-405 mln (previously $360-380 mln), Reuters consensus is $371 mln.
4:10PM NT prelim $0.11 with items; revs $2.83 bln vs $2.44 bln consensus :
4:10PM GlobeSpan Virata beats by a penny, ex items (GSPN) 7.61 -0.55: Reports Q4 (Dec) earnings of $0.07 per share, excluding items, $0.01 better than the Reuters Research consensus of $0.06; revenues rose 168.4% year/year to $137.3 mln vs the $129.8 mln consensus.
4:09PM Centillium misses by $0.02, ex items, misses on revs (CTLM) 6.36 -0.37: Reports Q4 (Dec) loss of $0.19 per diluted share, excluding approx $3.0 mln or ($0.08) in charges related to additional inventory reserves, $0.02 worse than the Reuters Research consensus of ($0.17); revenues rose 4.0% year/year to $25.7 mln vs the $28.9 mln consensus.
4:09PM Sapient reports in-line (SAPE) 6.28 +0.13: Reports Q4 (Dec) earnings of $0.01 per share, excluding a $1.4 mln gain on the sale of an investment, in line with the Reuters Research consensus of $0.01; revenues rose 23.7% year/year to $51.8 mln vs the $47.1 mln consensus. Note, revenue means service revenue only, not total gross revenue.
4:09PM Interwoven beats by $0.03, pro forma (IWOV) 14.20 -0.78: Reports Q4 (Dec) loss of $0.03 per share, pro forma, $0.03 better than the Reuters Research consensus of ($0.06); revenues rose 8.2% year/year to $33.6 mln vs the $33.1 mln consensus.
6:10PM Business Week discusses TELK : Business Week states that Telik (TELK) may be the next biotech buyout. So says Mark Monane of Needham, best known for calling the Pfizer (PFE) purchase of Esperion (ESPR). As of today's close TELK has soared to $24.00 up from Feb. level of $10.00. Monane says TELK could be next because its Telcyta is the "most promising unpartnered, small-molecule compound in late-stage development." Monane expects FDA approval for Telcyta by 2006. Telcyta targets breast, colon, lung, and ovarian cancer. With $222 mln in cash, TELK could bring Telcyta to market but Monane sees TELK finding a European marketing partner this year that could end up buying it. Possible partners include Aventis (AVE) or GlaxoSmithKline (GSK).
6:10PM Allmerica Earnings Color (AFC) 20.61 +0.37: -- Update -- Reuters Reseach is telling us that the comparable actual is $0.57, excluding multiple items...see the 16:58 comment for the full earnings report.
6:04PM PeopleSoft color (PSFT) 22.99 -0.04: -- Update -- We are hearing that PSFT is trading down after hours because company failed to meet heightened expectations for license revs.
5:59PM BIV mentioned favorably in Business Week : Business Week comments on well-known investors who are buying Bioenvision (BIV), most notably a 27% accumulation of shares by George Soros. At today's close the stock is trading at $5.18, up 241% from the July level of $2.15. Peter Cardillo, chief strategist at S.W. Bach, says BIV is undervalued not only because of the potential of its two staple drugs, Modrenal and Clofarabine, but also because it could be acquired. A logical buyer is Schering (SHR) or Bristol-Myers Squibb (BMY), he says, adding the stock is worth $10.00 in a buyout. CFO David Luci says BIV is looking for partners and concedes that some big companies are interested. The issue before the board, on which Soros is represented, is whether to go it alone or seek a merger to take advantage of the $1 bln market potential for Clofarabine..
5:52PM PeopleSoft beats by a penny, ex items (PSFT) 21.81 -1.17: Reports Q4 (Dec) pro forma earnings of $0.20 per share, excluding impact of deferred maintenance write-down of ($0.08), amortization of capitalized software and intangible assets of ($0.05), and restructuring charges of ($0.02), $0.01 better than the Reuters Research consensus of $0.19; revenues rose 33.7% year/year to $685.2 mln vs the $666.2 mln consensus.
5:51PM PeopleSoft license revs $185, at high end of guidance (PSFT) 22.99 -0.04:
5:51PM MicroStrategy reports EPS of $0.67 (MSTR) 53.50 -2.18: -- Update -- Reuters Research is indicating that excluding items the $0.67 actual is comparable to the $0.46 consensus... see 16:26 entry for full earnings comment.
5:51PM PeopleSoft beats Reuters conensus by $0.01, in line with First Call (PSFT) 22.99 -0.04:
5:47PM USF Corp reports results (USFC) 35.77 +0.47: Reports Q4 (Dec) earnings of $0.68, which includes ex items and is not comparable to consensus. After backing out a $5.5 mln net after-tax benefit or $0.20 per share ($6.1 mln gain from sale of a terminal net of a $0.6 mln restructuring charge.), we came up with $0.48 per share. Reuters Research consensus is $0.49, in touch with Reuters to confirm comparable actual; revenues fell 5.9% year/year to $546.6 mln vs the $572.8 mln consensus.
5:39PM Business Week comments on HON future : Business Week states that many analysts are sour on Honeywell International (HON), but some investors are buying shares because they smell a takeover. The talk is that United Technologies (UTX) will make a third pass. UTX made a bid in Oct but was edged out by General Electric (GE). The European Commission blocked GE's bid and UTX tried again but was turned down flat. John Inch of Merrill Lynch, who tags the stock a buy just on fundamentals, says UTX is still very interested -- and frustrated. But he doubts Honeywell is eager for a deal Honeywell rose from $26.00 in Sept to $35.95 at today's close. Richard Steinberg of Steinberg Global Asset Mgmt, who owns shares, says aerospace is poised to turn around, which would be a boon to HON.
5:39PM Chordiant Sftwr reports, guides in line (CHRD) 5.20 -0.23: Reports Q4 (Dec) earnings of $0.02 per share, in line with the Reuters Research consensus of $0.02; revenues rose 14.6% year/year to $19.6 mln vs the $18.9 mln consensus. Company sees Q1 revenues of $19-20 mln, consensus $19.1 mln.
5:32PM Overnite beats by $0.04, affirms Q1 (OVNT) 22.98 -0.05: Reports Q4 (Dec) earnings of $0.38 per share, ex-items, $0.04 better than the Reuters Research consensus of $0.34; revenues rose 7.7% year/year to $378.1 mln vs the $372.0 mln consensus. Co sees Q1 (Mar) EPS of $0.19-$0.24 vs consensus of $0.21.
5:32PM VeriSign provides mixed Q1 guidance (VRSN) 16.35 -1.41: -- Update -- On the conference call, management indicates that Q1 revenues are expected to be approximately $220 mln and EPS roughly $0.13. This compares to Reuters Research consensus of $228 mln in revenues and earnings of $0.13 per share. Gross margins are expected to be relatively flat at 60%, with operating margins in the 19-20% range.
5:28PM Roxio to consolidate offices, management teams (ROXI) 4.20 -0.15: Company announces it will consolidate management teams into Napster's L.A. office, Brad Duea, Head of Bus Dev, will become President, position held currently by Mike Bebel, who will "wind down" his New York based duties.
5:15PM Universal Health preannounces Q4 EPS below consensus, guides Y04 EPS below, revs above (UHS) 52.25 -0.15: Company expects to report adjusted Q4 EPS $0.73 vs the Reuters Research consensus of $0.75. Co also guides Y04, sees EPS of $3.43-3.53, vs the R.R. consensus of $3.56, and revenues exceeding $4.2 bln; the R.R. consensus is $4.02 bln.
5:09PM RadiSys reports for Q4, beats on revs (RSYS) 22.21 -0.64: Co is reporting Q4 (Dec) EPS of $0.08, which includes a $1.8 mln loss on sale of a building and a $200K gain on reversal of restructuring charge. After backing out these items co's EPS is approx $0.17. We are checking with Reuters for a comparable number against their consensus of $0.14 per share: revenues rose 17.0% year/year to $55.3 mln vs the $51.8 mln consensus.
5:09PM General Dynamics wins $8.4 bln multi-year contract (GD) 93.66 +1.21: Co announces that the U.S. Navy has entered into an $8.4 bln multi-year contract with General Dynamics Electric Boat for the procurement of 5 Virginia-class attack submarines from FY04 through FY08.
5:07PM Duquesne Light reports (DQE) 18.63 -0.02: Reports Q4 (Dec) earnings of $0.19 per share, $0.01 worse than the Reuters Research consensus of $0.20 and $0.01 better than First Call consensus of $0.18. Company affirms its Y04 earnings guidance of $80-85 mln.
5:07PM IMPAC Mortgage announces $100 mln common stock offering (IMH) 20.33 +0.63:
5:06PM Gateway reports in-line Q4 results (GTW) 4.09 +0.04: Reports Q4 (Dec) loss of $0.15 per share, in line with the Reuters Research consensus of ($0.15); revenues fell 17.2% year/year to $875.1 mln vs guidance of approx $880 mln and consensus of $880.2 mln.
5:03PM TELK: Telik may be the next biotech buyout -- Business Week 24.00 +0.30: Also mentioned in Business Week are Bioenvision (BIV) -- George Soros has accumulated 27% stake in little-known biopharma; and Honeywell (HON) -- many analysts are sour on Honeywell, "but some investors are buying shares because they smell a takeover."
5:03PM Chartered Semi reports in line, guides Q1 above consensus (CHRT) 10.16 -0.34: Reports Q4 (Dec) loss of $0.17 per ADS, in line with the Reuters Research consensus of ($0.17); revenues rose 69.4% year/year to $182.8 mln vs the $174.1 mln consensus. Co also guides Q1, sees loss per ADS of $0.05 to loss of $0.01, vs the R.R. consensus of ($0.19), and revenues of $221-227 mln, excluding CHRT's share of SMP, vs an estimate of $170.5 mln.
5:01PM Newport beats by $0.01; guides higher for Q1 (NEWP) 19.72 -0.24: Reports Q4 (Dec) loss of $(0.03) per share, excluding a $1.0 mln pre-tax or a $0.01 after-tax per share restructuring and impairment charge, $0.01 better than the Reuters Research consensus of ($0.04); revenues rose 11.7% year/year to $36.2 mln vs the $35.4 mln consensus. For Q1, co expects sales and EPS of $38.0-$39.5 mln and $0.00-$0.02 vs consensus of $36.9 mln and $(0.02).
4:59PM Guitar Center beats by $0.03; reaffirms Q1 guidance (GTRC) 32.75 -0.13: Reports Q4 (Dec) earnings of $0.78 per share, $0.03 better than the Reuters Research consensus of $0.75; revenues rose 18.2% year/year to $395.8 mln vs the $393.3 mln consensus. Co reaffirms Q1 (Mar) EPS guidance of $0.31-0.34 and revenues in the range of $323-334 mln, Reuters consensus is $0.32 and $329, respectively.
4:58PM Allmerica reports (AFC) 34.45 -0.25: Reports Q4 (Dec) earnings of $0.57 per share, excluding multiple items, $0.26 better than the Reuters Research consensus of $0.31.
4:55PM RSA Security reports in line; guides Q1 in line (RSAS) 15.53 -0.26: Reports Q4 (Dec) earnings of $0.10 per share, in line with the Reuters Research consensus of $0.10; revenues rose 15.9% year/year to $70.7 mln vs the $68.2 mln consensus. Company sees Q1 EPS of $0.06-0.09 on revs $68-71 mln vs the R.R. consensus of $0.08 & $67.1 mln respectively.
4:52PM Micrel tops consensus (MCRL) 16.70 -0.48: Reports Q4 (Dec) earnings of $0.05 per share, excluding a half-penny charge for stock compensation expense, $0.02 better than the Reuters Research consensus of $0.03; revenues rose 15.1% year/year to $58.3 mln vs the $57.2 mln consensus.
4:52PM Columbia Sportswear beats by $0.02 (COLM) 53.66 +0.53: Reports Q4 (Dec) earnings of $0.79 per share, $0.02 better than the Reuters Research consensus of $0.77; revenues rose 18.5% year/year to $257.4 mln vs the $249.0 mln consensus. For Q104, co sees net income growth of 14-16% and year-over-year revenue growth of 19-21%.
4:50PM Telecom/Networking stocks lift on Nortel report: AVCI +0.80, CSCO +0.40, JNPR +0.32, CIEN +0.30 :
4:49PM Nortel Earnings Color (NT) 7.94 +1.36: -- Update -- Reuters Research is indicating that excluding items the $0.09 actual is comparable to the $0.02 consensus... see 16:22 update for full earnings comment.
4:48PM Ascential beats by a penny, issues guidance (ASCL) 24.08 -0.80: Reports Q4 (Dec) earnings of $0.09 per share, $0.01 better than the Reuters Research consensus of $0.08; revenues rose 89.1% year/year to $64.5 mln vs the $63.2 mln consensus. Co expects Q1 revenue of $61-$64 mln (consensus $61.9 mln), and expects 2004 rev of $265-$275 mln (consensus $273.2 mln); co continues to anticipate GAAP profitability in each qtr of 2004.
4:47PM Avid Tech beats Q4 consensus, beat on revs (AVID) 48.97 -4.13: Co is reporting Q4 EPS of $0.47, which includes a $1.3 mln restructuring charge. After backing out charge co's Q4 EPS is approx $0.51, ex items. Reuters Research consensus of $0.46, checking with Reuters for a comparable number, but the co beat consensus either way; revenues rose 12.9% year/year to $127.3 mln vs the $125.4 mln consensus.
4:46PM Neurocrine Biosci reports (NBIX) 57.55 +0.18: Reports Q4 (Dec) earnings of $0.09 per diluted share, which includes a gain of $18.0 mln, or approx $0.48 per share, related to sale of current corporate facility, may not be comparable to the Reuters Research consensus of ($0.12); revenues rose 599.5% year/year to $27.1 mln vs the $35.1 mln consensus. Co anticipates 2004 to be a pivotal yearas it transitions from an R&D biotech company to a fully integrated pharmaceutical company.
4:45PM Eastman Chem beats, guides in line (EMN) 38.50 +0.15: Reports Q4 (Dec) earnings of $0.13 per share, "excluding certain items", $0.11 better than the Reuters Research consensus of $0.02; revenues rose 9.0% year/year to $1.43 bln vs the $1.38 bln consensus. Company sees Q1 EPS in line with consensus of $0.22.
4:41PM Intl Rectifier beats by $0.02, pro forma (IRF) 48.25 +0.03: Reports Q2 (Dec) earnings of $0.36 per share, pro forma, $0.02 better than the Reuters Research consensus of $0.34; revenues rose 20.4% year/year to $252.3 mln vs the $248.7 mln consensus.
4:41PM Exult reports in-line (EXLT) 7.10 -0.19: Reports Q4 (Dec) earnings of $0.05 per share, in line with the Reuters Research consensus of $0.05; revenues fell less than 1% to $117.9 mln. Note, revenue consensus was $132.7 mln, however, in Nov 2003, the co decided to sell certain assets and to divest the Gunn Partners consulting unit. The latter is now considered discontinued operations and is excluded from the $117.9 mln figure, but it appears that revenue from Gunn remained in the consensus.
4:39PM Magma Design beats by $0.02, ex items, beats on revs; guides in line for Q1 (LAVA) 26.76 +0.05: Reports Q3 (Dec) earnings of $0.16 per share, $0.02 better than the Reuters Research consensus of $0.14; revenues rose 66.3% year/year to $31.1 mln vs the $28.6 mln consensus. Co sees Q4 (Mar) EPS of $0.15-0.19, ex items, and revenues in the range of $32-34 mln, Reuters consensus is $0.17 and $32 mln, respectively.
4:38PM InterMune reports Q4 results, issues guidance (ITMN) 19.28 -0.30: Reports Q4 (Dec) loss of $0.73 per share, $0.41 better than the Reuters Research consensus of ($1.14); total net revenues rose 1.3% year/year to $39.8 mln vs the $40.1 mln consensus. Co expects 2004 total net product sales of $150-$180 mln, vs consensus of $177.4 mln; net product sales for Actimmune are projected to be in the range of $130-$155 mln for the year, and sales of Infergen are expected to be between $17-$22 mln.
4:35PM Borland beats by $0.02, ex items; guides in line (BORL) 9.30 -0.05: Reports Q4 (Dec) earnings of $0.06 per share, ex items, $0.02 better than the Reuters Research consensus of $0.04; revenues rose 10.4% year/year to $74.0 mln vs the $72.0 mln consensus. Company sees Q1 EPS of $0.03-0.05 vs the Reuters Research consensus of $0.04, on revs of $71-75 mln vs consensus of $72.7 mln.
4:35PM Advent Software reports, guides Q1 & Y04 revs in line (ADVS) 20.61 +0.37: Reports Q4 (Dec) earnings of $0.07 per share, excluding charges of approx ($2.38) related to tax provision of $70.5 mln, to record full valuation allowance against deferred tax assets, restructuring and impairment charges and amortization of intangibles of $5.9 mln, and a $1.8 mln write-off of internally developed software, may not be comparable to the Reuters Research consensus of $0.02; revenues rose 1.7% year/year to $36.9 mln vs the $36.3 mln consensus. Co also guides, sees Q1 revenues of $33.5-35.5 mln, vs an R.R. estimate $33.7 mln, and sees Y04 revenues of $145-150 mln vs an estimate of $145.6 mln. In touch with Reuters Research.
4:34PM Dendrite beats by $0.05, ex items; guides Q1 EPS above consensus (DRTE) 14.26 -0.22: Reports Q4 (Dec) earnings of $0.20 per share, $0.05 better than the Reuters Research consensus of $0.15; revenues rose 73.6% year/year to $99.0 mln.
4:34PM Tripos announces 10% reduction in Pfizer contract value (TRPS) 6.58 +0.17: Co announces an amendment to its strategic collaboration with Pfizer (PFE) for the design, synthesis and purification of druglike compounds. Tripos will reduce file enrichment activities with Pfizer, but partially offsetting this reduction, Tripos will engage in new work for Pfizer in the areas of hit follow-up and large library production.. Terms of the amended agreement result in a decrease in the total contract value of approx 10%, with the bulk of the reduction occurring in 2005.
4:33PM Exponent reports in-line (EXPO) 24.29 -0.06: Reports Q4 (Dec) earnings of $0.27 per share, in line with the Reuters Research consensus of $0.27; revenues rose 4.4% year/year to $34.3 mln vs the $31.7 mln consensus.
4:33PM LAVA prelim $0.16, 2 cents ahead; revs $31.1 mln vs $28.6 mln consensus :
4:32PM LivePerson reports in-line Q4, issues guidance (LPSN) 5.34 -0.32: Co reports Q4 EPS of $0.01 on $3.5 mln in sales, in-line with consensus of $0.01 and $3.45 mln. Co expects Q1 GAAP EPS of $0.01 on $4.0 mln in sales (consensus $0.02 and $3.92 mln), and expects 2004 GAAP EPS of $0.08 on $18.5 mln in sales (consensus $0.12 and $18.8 mln)... EPS ests may not be comparable, since it is unclear whether Q1 and 2004 EPS ests are GAAP or pro forma.
4:31PM PIXR resumes trading, advances 1.80 pts :
4:29PM Digital Insight beats by $0.02 (DGIN) 25.05 +0.96: Reports Q4 (Dec) earnings of $0.22 per share, ex items, $0.02 better than the Reuters Research consensus of $0.20; revenues rose 22.9% year/year to $42.2 mln vs the $40.9 mln consensus. Company sees Q1 pro forma EPS of $0.21-0.22 vs consensus of $0.21 on revs of $45-45.5 mln, consensus $42.8 mln. DGIN sees Y04 EPS of $0.92-0.96 vs consensus of $0.94 on revs of $193-197 mln, consensus is $179 mln.
4:29PM Packeteer reports in line (PKTR) 18.96 -0.44: Reports Q4 (Dec) earnings of $0.10 per share, in line with the Reuters Research consensus of $0.10; revenues rose 28.2% year/year to $20.0 mln vs the $19.5 mln consensus.
4:27PM Varian Semi beats by $0.02; guides sharply higher for MarQ (VSEA) 43.73 -0.12: Reports Q1 (Dec) earnings of $0.13 per share, $0.02 better than the Reuters Research consensus of $0.11; revenues rose 21.7% year/year to $101.8 mln vs the $100.0 mln consensus. Co expects Q2 (Mar) revenue and EPS of $120-$130 mln and $0.32-$0.40 vs consensus of $109 mln and $0.17.
4:26PM MicroStrategy reports for Q4, beats on revs; guides for Q1 and Y04 (MSTR) 53.50 -2.18: Co is reporting Q4 EPS of $1.02 which contains numerous gains. After backing out a $800K gain from discontinued operations and a $5.2 mln tax benefit, EPS is approx $0.63. We are checking with Reuters for a comparable number against the Reuters Research consensus of $0.46. But it does appear that the company has beaten estimates; revenues rose 23.1% year/year to $51.7 mln vs the $45.5 mln consensus. Co also beats on license revenues, reporting $23.4 mln vs Briefing.com license revenues consensus of $19.8 mln (2 analyst in survey). Co also sees Q1 GAAP EPS in the range of $0.14-0.26 and revenues in the range of $40-43 mln, consensus is $45 mln. Y04 GAAP EPS is in the range of $1.79-1.90 and revenues are in the range of $185-195 mln, consensus is $184 mln.
4:26PM Actuate reports in line, ex items (ACTU) 3.24 -0.07: Reports Q4 (Dec) non-GAAP earnings of $0.02 per diluted share, in line with the Reuters Research consensus of $0.02; revenues rose 0.4% year/year to $27.4 mln vs the $27.4 mln consensus.
4:22PM Nortel beats, guides (NT) 6.59 +0.13: Reports Q4 (Dec) earnings of $0.09 per share, $0.07 better than Reuters Research consensus of $0.02; revenues rose 11.9% year/year to $2.83 bln vs the $2.44 bln consensus. Company says it expects "seasonal decline" from this quarter's revenues of $2.83 bln, consensus $2.33 bln.
4:22PM CNET beats by $0.02 (CNET) 8.19 -0.25: Reports Q4 (Dec) earnings of $0.05 per share, $0.02 better than the Reuters Research consensus of $0.03; revenues rose 8.4% year/year to $73.5 mln vs the $70.1 mln consensus. For Q1, co sees total revenue of $60-$62 mln vs consensus of $60.8 mln.
4:19PM Yellow Roadway misses by $0.07, ex items, guides Q1 below consensus, Y04 in line (YELL) 36.41 +0.33: Reports Q4 (Dec) adjusted earnings of $0.71 per diluted share, excluding $0.73 per share of costs primarily attributed to acquisition of Roadway and its results of operations, $0.07 worse than the Reuters Research consensus of $0.78; revenues rose 18.5% year/year to $903.4 mln vs the $930.3 mln consensus. Co also guides, sees Q1 EPS of $0.25-0.35, vs the R.R. consensus of $0.36, and Y04 EPS of $2.70-3.30, vs the R.R. consensus of $3.08.
4:19PM TEKELEC beats by $0.03, ex items; guides (TKLC) 18.02 -0.01: Reports Q4 (Dec) earnings of $0.13 per share, ex items, $0.03 better than the Reuters Research consensus of $0.10; revenues rose 28.4% year/year to $75.0 mln vs the $73.1 mln consensus. Company sees Q1 EPS of $0.05-0.07 on revs of $73-75 mln vs the R.R. consensus of $0.07 & $68.32 respectively.
4:18PM BE Aerospace lowers Q4 guidance due to worsening conditions in the biz jet industry, weak dollar (BEAV) 6.26 -0.62:
4:16PM MicroStrategy beat on license revs, $23.4 mln vs consensus $19.8 mln :
4:16PM Avnet beats by $0.03 (AVT) 24.46 -1.13: Reports Q2 (Dec) earnings of $0.21 per share, ex-items, $0.03 better than the Reuters Research consensus of $0.18; revenues rose 8.9% year/year to $2.55 bln vs the $2.53 bln consensus.
4:12PM Lexar Media beats by a nickel, guides EPS below consensus (LEXR) 15.44 -0.21: Reports Q4 (Dec) earnings of $0.21 per share, $0.05 better than the Reuters Research consensus of $0.16; total revenues rose 171.0% year/year to $177.5 mln vs the $141.1 mln consensus. Co expects Q1 EPS of $0.10 in EPS on $140 mln in sales (consensus $0.13 and $121.1 mln), and expects 2004 EPS of $0.60 (consensus is $0.67).
4:12PM RealNetworks beats by $0.01, ex items, guides Q1 EPS below consensus (RNWK) 6.14 -0.30: Reports Q4 (Dec) non-GAAP loss of $0.02 per share, excluding ($0.01) related to litigation expenses, $0.01 better than the Reuters Research consensus of ($0.03); revenues rose 17.0% year/year to $54.1 mln vs the $54.8 mln consensus. Co also guides Q1, sees loss of $0.02 to loss of $0.03, vs the R.R. consensus of ($0.01), and revenues of $56-59 mln, vs an estimate of $57.8 mln.
4:12PM VeriSign beats by $0.04 (VRSN) 17.76 -0.86: Reports Q4 (Dec) fully taxed, pro forma earnings of $0.17 per share, $0.04 better than the Reuters Research consensus of $0.13; revenues fell 8.5% year/year to $251.6 mln vs the $244.7 mln consensus. Company reported $0.18 per share on an untaxed basis.
4:11PM LEXR turns south on guidance; watch for potential weakness in SNDK :
4:11PM California Pizza reports in line, guides Q1 below consensus (CPKI) 18.10 -0.31: Reports Q4 (Dec) earnings of $0.22 per share, in line with the Reuters Research consensus of $0.22; revenues rose 17.8% year/year to $96.0 mln vs the $95.5 mln consensus. Company sees Q1 EPS of $0.17-0.19 vs consensus of $0.23, reaffirms Y04 outlook of $0.95-1.05 vs consensus of $0.96.
4:11PM Adobe Systems increases Q1 guidance (ADBE) 36.13 -0.51: Based on strong results thus far in the quarter Co says it will exceed previous financial targets provided. Increases it Q1 (Feb) EPS to $0.36-0.42 (previously $0.33-0.36), Reuters consensus is $0.35 and revenues to the range of $380-405 mln (previously $360-380 mln), Reuters consensus is $371 mln.
4:10PM NT prelim $0.11 with items; revs $2.83 bln vs $2.44 bln consensus :
4:10PM GlobeSpan Virata beats by a penny, ex items (GSPN) 7.61 -0.55: Reports Q4 (Dec) earnings of $0.07 per share, excluding items, $0.01 better than the Reuters Research consensus of $0.06; revenues rose 168.4% year/year to $137.3 mln vs the $129.8 mln consensus.
4:09PM Centillium misses by $0.02, ex items, misses on revs (CTLM) 6.36 -0.37: Reports Q4 (Dec) loss of $0.19 per diluted share, excluding approx $3.0 mln or ($0.08) in charges related to additional inventory reserves, $0.02 worse than the Reuters Research consensus of ($0.17); revenues rose 4.0% year/year to $25.7 mln vs the $28.9 mln consensus.
4:09PM Sapient reports in-line (SAPE) 6.28 +0.13: Reports Q4 (Dec) earnings of $0.01 per share, excluding a $1.4 mln gain on the sale of an investment, in line with the Reuters Research consensus of $0.01; revenues rose 23.7% year/year to $51.8 mln vs the $47.1 mln consensus. Note, revenue means service revenue only, not total gross revenue.
4:09PM Interwoven beats by $0.03, pro forma (IWOV) 14.20 -0.78: Reports Q4 (Dec) loss of $0.03 per share, pro forma, $0.03 better than the Reuters Research consensus of ($0.06); revenues rose 8.2% year/year to $33.6 mln vs the $33.1 mln consensus.
